Abstract
Purpose
To assess the success rate of first dose radioiodine for treatment of hyperthyroidism in children and adolescent.
Methods
This is a retrospective data analysis of children and adolescent with hyperthyroidism who received radioiodine (RAI) therapy from January 2013 to December 2017. Age, gender, family history of hyperthyroidism, duration of anti-thyriod drugs (ATDs) treatment, rapid turnover status, 2 h and 24 h I-131 radioiodine uptake (RAIU), thyroid volume, and treatment dose were also analyzed. The goal of RAI therapy was to achieve hypothyroidism within 3–6 months after treatment. Treatment result was evaluated at 6 months after treatment and divided into 2 groups: treatment success (hypothyroid and euthyroid) and treatment failure (hyperthyroid). The same parameters were compared between both groups.
Results
32 hyperthyroid patients, 26 female with mean age at treatment of 13.84 ± 1.83 years. All patients had prior treatment with ATDs, with a median treatment duration of 32.5 months (range 2–108). The median estimated thyroid gland size was 24.62 g, range 9.29–72.8. RAI doses ranged from 4.1 to 29.9 mCi (median dose = 7.54 mCi). Significant difference in 24-h I-131 uptake and RI status was demonstrated. Successful treatment rate after single dose of therapeutic I-131 was 65.63%.
Conclusion
With the I-131 dose of 220 μCi/g of thyroid tissue, successful treatment rate after single dose of therapeutic I-131 was 65.63%. RAI therapy with I-131 dose of 250–400 μCi/g of thyroid tissue might be suitable in patients with medical failure from ATDs. Possible role of RI as the predictor for RAI therapy failure are needed to investigate in both adult and children clinical settings.
Similar content being viewed by others
References
Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, Izumi M (1991) Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid 1(2):129–135. https://doi.org/10.1089/thy.1991.1.129
Leech NJ, Dayan CM (1998) Controversies in the management of Graves' disease. Clin Endocrinol 49(3):273–280. https://doi.org/10.1046/j.1365-2265.1998.00558.x
Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Torring O (2008) TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 158(1):69–75. https://doi.org/10.1530/EJE-07-0450
Traisk F, Tallstedt L, Abraham-Nordling M, Andersson T, Berg G, Calissendorff J, Hallengren B, Hedner P, Lantz M, Nystrom E, Ponjavic V, Taube A, Torring O, Wallin G, Asman P, Lundell G, Thyroid Study Group of TT (2009) Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab 94(10):3700–3707. https://doi.org/10.1210/jc.2009-0747
Namwongprom S, Unachak K, Dejkhamron P, Ua-apisitwong S, Ekmahachai M (2013) Radioactive iodine for thyrotoxicosis in childhood and adolescence: treatment and outcomes. J Clin Res Pediatr Endocrinol 5(2):95–97. https://doi.org/10.4274/Jcrpe.951
Brunn J, Block U, Ruf G, Bos I, Kunze WP, Scriba PC (1981) Volumetric analysis of thyroid lobes by real-time ultrasound (author's transl). Dtsch Med Wochenschr 106(41):1338–1340. https://doi.org/10.1055/s-2008-1070506
Rivkees SA (2006) The treatment of Graves' disease in children. J Pediatr Endocrinol Metab 19(9):1095–1111. https://doi.org/10.1515/jpem.2006.19.9.1095
Hamburger JI (1985) Management of hyperthyroidism in children and adolescents. J Clin Endocrinol Metab 60(5):1019–1024. https://doi.org/10.1210/jcem-60-5-1019
Glaser NS, Styne DM (1997) Predictors of early remission of hyperthyroidism in children. J Clin Endocrinol Metab 82(6):1719–1726. https://doi.org/10.1210/jcem.82.6.3986
Glaser NS, Styne DM, Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study G (2008) Predicting the likelihood of remission in children with Graves' disease: a prospective, multicenter study. Pediatrics 121(3):e481–488. https://doi.org/10.1542/peds.2007-1535
Kaguelidou F, Alberti C, Castanet M, Guitteny MA, Czernichow P, Leger J, French Childhood Graves' Disease Study G (2008) Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab 93(10):3817–3826. https://doi.org/10.1210/jc.2008-0842
Ron E, Doody MM, Becker DV, Brill AB, Curtis RE, Goldman MB, Harris BS 3rd, Hoffman DA, McConahey WM, Maxon HR, Preston-Martin S, Warshauer ME, Wong FL, Boice JD Jr (1998) Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA 280(4):347–355. https://doi.org/10.1001/jama.280.4.347
Rivkees SA, Dinauer C (2007) An optimal treatment for pediatric Graves' disease is radioiodine. J Clin Endocrinol Metab 92(3):797–800. https://doi.org/10.1210/jc.2006-1239
Ma C, Kuang A, Xie J, Liu G (2008) Radioiodine treatment for pediatric Graves' disease. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD006294.pub2
Nebesio TD, Siddiqui AR, Pescovitz OH, Eugster EA (2002) Time course to hypothyroidism after fixed-dose radioablation therapy of Graves' disease in children. J Pediatr 141(1):99–103. https://doi.org/10.1067/mpd.2002.125494
Rivkees SA, Cornelius EA (2003) Influence of iodine-131 dose on the outcome of hyperthyroidism in children. Pediatrics 111(4 Pt 1):745–749. https://doi.org/10.1542/peds.111.4.745
Allahabadia A, Daykin J, Sheppard MC, Gough SC, Franklyn JA (2001) Radioiodine treatment of hyperthyroidism-prognostic factors for outcome. J Clin Endocrinol Metab 86(8):3611–3617. https://doi.org/10.1210/jcem.86.8.7781
Rivkees SA, Sklar C, Freemark M (1998) Clinical review 99: The management of Graves' disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab 83(11):3767–3776. https://doi.org/10.1210/jcem.83.11.5239
Rivkees SA (2016) Controversies in the management of Graves' disease in children. J Endocrinol Invest 39(11):1247–1257. https://doi.org/10.1007/s40618-016-0477-x
Levy WJ, Schumacher OP, Gupta M (1988) Treatment of childhood Graves' disease. A review with emphasis on radioiodine treatment. Cleve Clin J Med 55(4):373–382. https://doi.org/10.3949/ccjm.55.4.373
Azizi F, Amouzegar A (2018) Management of thyrotoxicosis in children and adolescents: 35 years' experience in 304 patients. J Pediatr Endocrinol Metab 31(2):159–165. https://doi.org/10.1515/jpem-2017-0394
Kaplowitz PB, Jiang J, Vaidyanathan P (2020) Radioactive iodine therapy for pediatric Graves' disease: a single-center experience over a 10-year period. J Pediatr Endocrinol Metab 33(3):383–389. https://doi.org/10.1515/jpem-2019-0316
Leger J, Oliver I, Rodrigue D, Lambert AS, Coutant R (2018) Graves' disease in children. Ann Endocrinol 79(6):647–655. https://doi.org/10.1016/j.ando.2018.08.001
De Luca F, Valenzise M (2018) Controversies in the pharmacological treatment of Graves' disease in children. Expert Rev Clin Pharmacol 11(11):1113–1121. https://doi.org/10.1080/17512433.2018.1546576
Aung ET, Zammitt NN, Dover AR, Strachan MWJ, Seckl JR, Gibb FW (2019) Predicting outcomes and complications following radioiodine therapy in Graves' thyrotoxicosis. Clin Endocrinol 90(1):192–199. https://doi.org/10.1111/cen.13873
Aktay R, Rezai K, Seabold JE, Bar RS, Kirchner PT (1996) Four- to twenty-four-hour uptake ratio: an index of rapid iodine-131 turnover in hyperthyroidism. J Nucl Med 37(11):1815–1819
Marcocci C, Gianchecchi D, Masini I, Golia F, Ceccarelli C, Bracci E, Fenzi GF, Pinchera A (1990) A reappraisal of the role of methimazole and other factors on the efficacy and outcome of radioiodine therapy of Graves' hyperthyroidism. J Endocrinol Invest 13(6):513–520. https://doi.org/10.1007/BF03348615
van Isselt JW, Broekhuizen-de Gast HS (2010) The radioiodine turnover rate as a determinant of radioiodine treatment outcome in Graves' disease. Hell J Nucl Med 13(1):2–5
Berg GE, Michanek AM, Holmberg EC, Fink M (1996) Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements. J Nucl Med 37(2):228–232
Kaplowitz PB, Vaidyanathan P (2020) Update on pediatric hyperthyroidism. Curr Opin Endocrinol Diabetes Obes 27(1):70–76. https://doi.org/10.1097/MED.0000000000000521
McCormack S, Mitchell DM, Woo M, Levitsky LL, Ross DS, Misra M (2009) Radioactive iodine for hyperthyroidism in children and adolescents: referral rate and response to treatment. Clin Endocrinol 71(6):884–891. https://doi.org/10.1111/j.1365-2265.2009.03565.x
Franklyn JA, Boelaert K (2012) Thyrotoxicosis. Lancet 379(9821):1155–1166. https://doi.org/10.1016/S0140-6736(11)60782-4
Funding
None.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All the authors declare that they have no conflicts of interest.
Ethical approval
This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Human Investigation Committee (IRB) of Faculty of Medicine, Chiang Mai University, Thailand approved this study.
Informed consent
For this type of study, inform consent is not required.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Namwongprom, S., Dejkhamron, P. & Unachak, K. Success rate of radioactive iodine treatment for children and adolescent with hyperthyroidism. J Endocrinol Invest 44, 541–545 (2021). https://doi.org/10.1007/s40618-020-01339-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40618-020-01339-w